BNP Paribas Financial Markets
NERV icon

BNP Paribas Financial Markets’s Minerva Neurosciences NERV Stock Holding History

BNP Paribas Financial Markets’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$374 Hold
62
– – ﹤0.01% 5566
2025
Q4 		$249 Hold
62
– – ﹤0.01% 5546
2025
Q3 		$131 Hold
62
– – ﹤0.01% 5422
2025
Q2 		$107 Hold
62
– – ﹤0.01% 5322
2025
Q1 		$105 Hold
62
– – ﹤0.01% 5251
2024
Q4 		$138 Buy
+62
New +$146 ﹤0.01% 5259
2022
Q2 		– Sell
-67
Closed -$442 – 4189
2022
Q1 		$442 Hold
67
– – ﹤0.01% 4029
2021
Q4 		$427 Sell
67
-5
-7% -$47 ﹤0.01% 4120
2021
Q3 		$1.01K Hold
72
– – ﹤0.01% 3873
2021
Q2 		$1.34K Sell
72
-503
-87% -$10.8K ﹤0.01% 3923
2021
Q1 		$13.4K Sell
575
-339
-37% -$8.47K ﹤0.01% 3805
2020
Q4 		$17.1K Sell
914
-105
-10% -$2.65K ﹤0.01% 3874
2020
Q3 		$25.9K Buy
1,019
+707
+227% +$19.1K ﹤0.01% 3741
2020
Q2 		$9K Sell
312
-905
-74% -$53.1K ﹤0.01% 3757
2020
Q1 		$58.6K Buy
1,217
+656
+117% +$39.6K ﹤0.01% 3467
2019
Q4 		$31.9K Sell
561
-41
-7% -$1.81K ﹤0.01% 3860
2019
Q3 		$37.3K Buy
602
+170
+39% +$9.63K ﹤0.01% 3641
2019
Q2 		$19.4K Sell
432
-369
-46% -$18.5K ﹤0.01% 3911
2019
Q1 		$50.3K Buy
801
+800
+80,000% +$48.1K ﹤0.01% 3490
2018
Q4 		$67 Sell
1
-139
-99% -$10.2K ﹤0.01% 4225
2018
Q3 		$14.1K Hold
140
– – ﹤0.01% 3585
2018
Q2 		$9.26K Sell
140
-526
-79% -$31.9K ﹤0.01% 3814
2018
Q1 		$33.3K Sell
666
-9
-1% -$432 ﹤0.01% 3749
2017
Q4 		$32.7K Buy
675
+112
+20% +$5.55K ﹤0.01% 3852
2017
Q3 		$34.2K Buy
563
+274
+95% +$15.7K ﹤0.01% 3341
2017
Q2 		$20.5K Buy
289
+279
+2,790% +$18.1K ﹤0.01% 3650
2017
Q1 		$664 Sell
10
-123
-92% -$9.55K ﹤0.01% 3794
2016
Q4 		$12.5K Sell
133
-32
-19% -$3.27K ﹤0.01% 3357
2016
Q3 		$18.6K Buy
165
+86
+109% +$8.35K ﹤0.01% 2933
2016
Q2 		$6.45K Buy
+79
New +$5.02K ﹤0.01% 3137

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM

BNP Paribas Financial Markets's NERV Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Minerva Neurosciences (NERV) position steady in Q1 2026 at 62 shares worth $374. The position accounts for ﹤0.01% of the portfolio, ranked #5566.

BNP Paribas Financial Markets first reported a position in NERV in Q2 2016 and has held it in 30 quarters since. The position peaked at $58.6K in Q1 2020. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • BNP Paribas Financial Markets held 62 shares of Minerva Neurosciences worth $374 as of Q1 2026.
  • BNP Paribas Financial Markets left its Minerva Neurosciences share count unchanged in Q1 2026.
  • Minerva Neurosciences made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5566 holding.
  • BNP Paribas Financial Markets first reported a position in Minerva Neurosciences in Q2 2016 and has held it in 30 quarters since.
  • BNP Paribas Financial Markets's Minerva Neurosciences position peaked at $58.6K in Q1 2020.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.